Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.65 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714319 | 0.88 | LMNA (0.58) | SCN3ANAMPTSCN9AALDH1A1MEN1 | |
| SCHEMBL711140 | 0.86 | RXFP1 (0.55) | SCN3ANAMPTALDH1A1PKMMEN1 | |
| SCHEMBL710421 | 0.86 | MEN1 (0.47) | SCN3ANAMPTPOLBALDH1A1PKM | |
| SCHEMBL711841 | 0.81 | KDM1A (0.64) | SCN3ASCN9AALDH1A1PKMATM | |
| SCHEMBL711424 | 0.80 | SCN3A (0.56) | SCN3APOLBALDH1A1PKMATM | |
| SCHEMBL713846 | 0.78 | SCN1A (0.56) | SCN3APOLBSCN9AALDH1A1PKM | |
| SCHEMBL714055 | 0.78 | PKM (0.54) | SCN3ANAMPTPOLBSCN9AALDH1A1 | |
| SCHEMBL712663 | 0.78 | LMNA (0.62) | SCN3ASCN9AALDH1A1MEN1KMT2A | |
| SCHEMBL712653 | 0.78 | SCN9A (0.61) | SCN3ASCN9A | |
| SCHEMBL711624 | 0.77 | SCN3A (0.63) | SCN3ANAMPTSCN9AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2173743-A2 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012242-A2 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | SCN3A 7/4885NAMPT 687/4885POLB 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.